

Ref. No.: QHTL/Sec/SE/2025-26/05
To,
The Manager,
Corporate Services,
BSE Limited,
14th Floor, P J Towers, Dalal Street,
Mumbai – 400 001
Ref: Security ID: QUICKHEAL
Security Code: 539678

May 06, 2025
To,
The Manager,
Corporate Services,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: QUICKHEAL
Series: EQ

Subject: Outcome of Board Meeting held on May 6, 2025.

Dear Sir / Madam,

We wish to inform you that the Board of Directors at its meeting held on May 6, 2025 which commenced at 05:00 PM IST and concluded at 9:29 PM, has approved following:

1. Audited Financial Results of the Company for the financial year ended March 31, 2025, both Standalone and consolidated.
2. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the regulations"), we have enclosed herewith Audit Report for the audited financial results both standalone and consolidated for the financial year ended March 31, 2025 from our Statutory Auditors M/s MSKA & Associates, Chartered Accountants.
3. A copy of the Press Release being issued in respect of the aforesaid financial results.
4. Investor Presentation in respect of aforesaid financial results.
5. Appointment of Ruchi Bhawe, Practicing Company Secretary (FCS: 13324/ CP: 27019) as the Secretarial Auditor of the Company for a period of Five years, i.e. for Financial year April 1, 2025 to March 31, 2030 subject to approval of members.

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the regulations"), a declaration that Statutory Auditors of the Company have issued an Audit Report with Unmodified opinion on the Audited Financial Results of the Company (Standalone and Consolidated) for the quarter and year ended March 31, 2025.

This is for your information and records.

For Quick Heal Technologies Limited

Vikram Dhanani
Compliance Officer

A. Quarterly and Annual Financial Results


QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED AND ITS SUBSIDIARIES FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025
(? in Crores, except earnings per share)

Sr. No.	Particulars	Quarter ended			Year ended	
		March 31, 2025 (refer note 1)	December 31, 2024 /Unaudited)	March 31, 2024 (refer note 1)	March 31, 2025 (Audited)	March 31, 2024 (Audited)
1	Income					
	Revenue from operations	65.14	70.61	80.03	279.53	291.75
	Other income	5.60	4.91	6.82	20.77	21.39
	Total income	70.74	75.52	86.85	300.30	313.14
2	Expenses					
	Cost of material consumed	1.01	1.68	-	6.10	0.41
	Purchase of security software products	-	-	1.39	0.45	5.13
	Changes in inventory of security software products	0.61	-	0.33	0.58	1.29
	Employee benefits expense	48.72	45.16	44.18	185.55	169.03
	Finance costs	0.06	0.06	0.13	0.22	0.13
	Depreciation and amortisation expense	3.63	3.39	3.18	12.96	12.60
	Other expenses	23.28	27.54	24.09	93.44	98.34
	Total expenses	77.31	77.83	73.30	299.30	286.93
3	Profit/(loss) before tax (1-2)	(6.57)	(2.31)	13.55	1.00	26.21
4	Tax expense					
	Current tax	(1.66)	(0.38)	2.81	-	5.78
	Adjustments of tax relating to earlier periods (Net)	-	0.44	0.07	0.44	0.07
	Deferred tax (benefit)	(1.66)	(2.48)	(3.37)	(4.48)	(3.88)
	Total tax expense/ (benefit)	(3.32)	(2.42)	(0.49)	(4.04)	1.97
5	Profit/ (loss) after tax (3-4)	(3.25)	0.11	14.04	5.04	24.24
6	Other comprehensive income/(loss) (net of tax)					
	Items that will not be reclassified subsequently to profit or loss :					
	Gain/ (loss) on re-measurement of defined benefit plans	(0.06)	0.17	0.16	(0.19)	(0.16)
	Net (loss) or gain on FVOCI instruments (refer note 3)	(0.17)	-	(0.90)	(0.17)	(13.45)
	Items that will be reclassified subsequently to profit or loss :					
	Exchange differences on translation of foreign operations	-	0.03	(0.02)	0.07	(0.06)
	Total other comprehensive income/ (loss) for the period	(0.23)	0.20	(0.76)	(0.29)	(13.67)
7	Total comprehensive income/(loss) (after tax) (5+6)	(3.48)	0.31	13.28	4.75	10.57
8	Paid-up equity share capital (face value of? 10 each, fully paid up)	54.00	53.92	53.51	54.00	53.51
9	Other equity excluding revaluation reserves as per balance sheet	-	-	-	387.48	383.49
10	Earnings/ (loss) per share of? 10 each: (not annualised except for the year ended March)					
	a) Basic	(0.60)	0.02	2.63	0.94	4.56
	b) Diluted	(0.60)	0.02	2.57	0.94	4.48



QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014


CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED AND ITS SUBSIDIARIES FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

Notes to financial results:

- 1 The Audited consolidated financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The above financial results for the quarter and year ended March 31, 2025 have been subjected to audit by the statutory auditors of the Holding Company and reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at the meeting held on May 06, 2025. Figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between the audited figures in respect of the full years and published year to date figures of nine months ended December 31, 2024 and December 31, 2023 respectively.
- 2 During the quarter and year ended March 31, 2025, the Regional P F Commissioner ("RPFC") passed an order under Section 7A & 7Q of the Employees' Provident Funds and Miscellaneous Provisions Act, 1952 ("Act") demanding ₹ 5.01 (including interest of ₹ 2.49) on the grounds that it failed to remit Provident Fund ("PF") on wages for its employees for the period from September 2014 to March 2019 for certain allowances of salary. The Holding Company filed an appeal before the Central Government Industrial Tribunal Cum-Labour Court ("CGIT") challenging the Employees' Provident Fund Organisation's ("EPFO") order along with the application under Section 70 of the Act seeking a waiver from pre-deposit of the alleged Provident Fund Contributions till the final disposal of the Appeal. The CGIT, after hearing the submissions made, passed an Order and directed RPFC, not to proceed with the recovery against the Holding Company on depositing 30% of the total amount assessed. The Holding Company, based on the legal counsel's opinion, is of the view that the claim made by the RPFC is not probable, and accordingly no provision is recorded in the financial results of the quarter and year ended March 31, 2025.
- 3 During the year ended March 31, 2024 considering the financial position, liquidity condition, market conditions and geopolitical scenario in Israel, management based on its assessment had recorded a fair value loss in other comprehensive income (FVOCI) amounting to ₹ 12.55. Accordingly, the carrying value of investment made in L7 Defense Limited has been considered as ₹ Nil as at March 31, 2024.
- 4 As at March 31, 2025, the Holding Company has the following subsidiaries:
 - a) Quick Heal Technologies America Inc.
 - b) Seqrite Technologies DMCC
- 5 The Group is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activinet products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 6 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune
Date: May 06, 2025




For and on behalf of the Board of Directors

Kailash Katkar
Chairman & Managing Director
DIN No: 00397191

QUICK HEAL TECHNOLOGIES LIMITED		
Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014		
CIN: L72200MH1995PLC091408		
STATEMENT OF CONSOLIDATED AUDITED ASSETS AND LIABILITIES AS AT MARCH 31, 2025		
	T in Crores	
	As at March 31, 2025 (Audited)	As at March 31, 2024 (Audited)
Assets		
Non-current assets		
(a) Property, plant and equipment	83.15	83.61
(b) Capital work-in-progress	0.05	3.06
(c) Investment Property	35.01	31.62
(d) Intangible assets	0.72	1.49
(e) Right-of-use assets	0.33	-
(f) Financial assets		
(i) Investments	7.28	7.45
(ii) Other financial assets	0.89	0.82
(g) Deferred tax assets (net)	7.94	3.40
(h) Income tax assets (net)	17.20	16.46
(i) Other non-current assets	1.35	0.91
	153.92	148.82
Current assets		
(a) Inventories	2.22	2.80
(b) Financial assets		
(i) Investments	172.01	182.51
(ii) Trade receivables	166.73	131.72
(iii) Cash and cash equivalents	20.84	37.51
(iv) Bank balances other than (iii) above	0.13	0.25
(v) Other financial assets	1.27	1.27
(c) Other current assets	7.92	7.75
	371.12	363.81
Total assets	525.04	512.63
Equity and liabilities		
Equity		
(a) Equity share capital	54.00	53.51
(b) Other equity	387.48	383.49
Total equity	441.48	437.00
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	0.09	-
(b) Employee benefit obligations	0.74	-
(c) Other non-current liabilities	4.02	2.33
	4.85	2.33
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	3.52	3.70
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	31.41	36.18
(ii) Other financial liabilities	1.76	3.82
(b) Employee benefit obligations	18.13	15.57
(c) Other current liabilities	23.88	14.02
(d) Income tax liabilities (net)	0.01	0.01
	78.71	73.30
Total liabilities	83.56	75.63
Total equity and liabilities	525.04	512.63




Quick Heal Technologies Limited Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408		
CONSOLIDATED AUDITED CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2025		
	? in Crores	
	March 31, 2025 Audited	March 31, 2024 Audited
A. Cash flow from operating activities		
Profit before tax	1 00	26.21
Adjustment to reconcile profit before tax to net cash flows:		
Net (gain)/ loss foreign exchange differences	(0.08)	(0.21)
Exchange difference on translation of foreign operations	0.07	-
Employee share based payments expense	9.95	5.10
Interest on lease	0.22	0.13
Rent equalisation	(0.21)	(0.12)
Depreciation and amortization expense	12.96	12.60
Interest income	(0.78)	(1.43)
Provision for doubtful debts and advances	3.92	7.15
Property, plant and equipment written off	-	0.32
(Profit) on sale of property, plant and equipment	(0.13)	(0.27)
Income from Investment Property	(5.49)	(4.99)
Net gain on sale of investment	(2.16)	(2.02)
Unrealised gain on investments	(11.30)	(10.23)
Operating profit before working capital changes	7.97	32.24
Movements in working capital:		
Increase in trade receivables	(38.83)	(16.07)
Decrease in inventories	0.58	1.70
(Increase)/decrease in other financial assets	(0.10)	0.50
(Increase) in other assets	(0.40)	(1.23)
Increase in net employee benefit obligations	3.05	14.18
Decrease in trade payables	(4.95)	(8.73)
Decrease in other financial liabilities	(0.10)	(10.23)
Increase in other current and non-current liabilities	11.33	5.80
Cash (used in)/ generated from operations	(21.45)	18.16
Income taxes paid (net of refund)	(0.85)	0.03
Net cash flow (used in)/ generated from operating activities (A)	(22.30)	18.19
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(14.42)	(7.56)
Proceeds from sale of property, plant and equipment	0.34	1.08
Purchase of investment in mutual funds	(265.10)	(279.68)
Proceeds from sale of investment in mutual funds	289.06	286.21
Rental income from investment property	5.49	4.99
Decrease in Deposits with remaining maturity of more than twelve months	0.14	0.02
Income interest received	0.46	1.09
Net cash flow generated from investing activities (B)	15.97	6.15
C. Cash flow from financing activities		
Dividend paid	(16.13)	(13.29)
Principal paid on lease liabilities	(0.10)	-
GST refund on buy back expenses	-	0.14
Refund of buy back tax	-	8.60
Proceeds from issuance of equity shares (including securities premium) on exercise of employee stock options	5.91	6.15
Net cash flow (used in)/ generated from financing activities (C)	(10.32)	1.60
Net (Decrease)/ increase in cash and cash equivalents (A+B+C)	(16.65)	25.94
Cash and cash equivalents at the beginning of the period	37.51	11.58
Effect of exchange differences on cash and cash equivalents held in foreign currency	(0.02)	(0.01)
Cash and cash equivalents at the end of the period	20.84	37.51
Components of cash and cash equivalents		
Cash on hand	0.01	0.01
Balances with banks		
On current account	13.63	7.11
On EEFC account	1.63	2.32
Deposits with original maturity of less than three months	5.57	28.07
Total cash and cash equivalents	20.84	37.51



A. Quarterly and Annual Financial Results

<p style="text-align: center;">QUICK HEAL TECHNOLOGIES LIMITED Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408</p>						
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025						
Sr. No.	Particulars	Quarter ended			Year ended	
		March 31, 2025 (refer note 1)	December 31, 2024 (Unaudited)	March 31, 2024 (refer note 1)	March 31, 2025 (Audited)	March 31, 2024 (Audited)
1	Income					
	Revenue from operations	65.13	70.54	80.03	279.53	291.75
	Other income	5.54	4.91	6.82	20.72	21.37
	Total income	70.67	75.45	86.85	300.25	313.12
2	Expenses					
	Cost of material consumed	1.03	1.60	*	6.11	0.41
	Purchase of security software products	-	♦	1.39	0.45	5.13
	Changes in inventory of security software products	0.61	♦	0.33	0.58	1.29
	Employee benefits expense	48.55	45.02	44.09	184.95	168.94
	Finance costs	0.06	0.06	0.13	0.22	0.13
	Depreciation and amortisation expense	3.63	3.39	3.18	12.96	12.60
	Other expenses	22.79	27.58	24.19	93.45	98.58
	Total expenses	76.67	77.65	73.31	298.72	287.08
3	Profit/(loss) before tax (1-2)	(6.00)	(2.20)	13.54	1.53	26.04
4	Tax expense					
	Current tax	(1.66)	(0.38)	2.81	-	5.78
	Adjustments of tax relating to earlier periods (Net)	*	0.44	0.07	0.44	0.07
	Deferred tax (benefit)	(1.66)	(2.48)	(3.37)	(4.48)	(3.88)
	Total tax expense/ (benefit)	(3.32)	(2.42)	(0.49)	(4.04)	1.97
5	Profit/ (loss) after tax (3-4)	(2.68)	0.22	14.03	5.57	24.07
6	Other comprehensive income/(loss) (net of tax)					
	Items that will not be reclassified subsequently to profit or loss :					
	Re-measurement of defined benefit-plans	(0.06)	0.17	0.16	(0.19)	(0.16)
	Net (loss) or gain on FVOCI instruments (refer note 3)	(0.17)	-	(0.90)	(0.17)	(13.45)
	Total other comprehensive income/(loss) for the period	(0.23)	0.17	(0.74)	(0.36)	(13.61)
7	Total comprehensive income/ (loss) (after tax) (5+6)	(2.91)	0.39	13.29	5.21	10.46
8	Paid-up equity share capital (face value of ₹ 10 each, fully paid up)	54.00	53.92	53.51	54.00	53.51
9	Other equity excluding revaluation reserves as per balance sheet	-	-	*	387.84	383.39
10	Earnings/ (loss) per share of ₹ 10 each: (not annualised except for the year ended March)					
	a) Basic	(0.50)	0.04	2.63	1.04	4.52
	b) Diluted	0.50	0.04	2.57	1.01	4.45




QUICK HEAL TECHNOLOGIES LIMITED
Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

Notes to financial results:

- 1** The Audited standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The above financial results for the quarter and year ended March 31, 2025 have been subjected to audit by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on May 06, 2025. Figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between the audited figures in respect of the full years and published year to date figures of nine months ended December 31, 2024 and December 31, 2023 respectively.
- 2** During the quarter and year ended March 31, 2025, the Regional P.F Commissioner ("RPFC") passed an order under Section 7A & 7Q of the Employees' Provident Funds and Miscellaneous Provisions Act, 1952 ("Act") demanding ₹ 5.01 (including interest of ₹ 2.49) on the grounds that it failed to remit Provident Fund ("PF") on wages for its employees for the period from September 2014 to March 2019 for certain allowances of salary. The Company filed an appeal before the Central Government Industrial Tribunal Cum-Labour Court ("CGIT") challenging the Employees' Provident Fund Organisation's ("EPFO") order along with the application under Section 70 of the Act seeking a waiver from pre-deposit of the alleged Provident Fund Contributions till the final disposal of the Appeal. The CGIT, after hearing the submissions made, passed an Order and directed RPFC, not to proceed with the recovery against the Company on depositing 30% of the total amount assessed. The Company, based on the legal counsel's opinion, is of the view that the claim made by the RPFC is not probable, and accordingly no provision is recorded in the financial results of the quarter and year ended March 31, 2025.
- 3** During the year ended March 31, 2024 considering the financial position, liquidity condition, market conditions and geopolitical scenario in Israel, management based on its assessment had recorded a fair value loss in other comprehensive income (FVOCI) amounting to ₹ 12.55. Accordingly, the carrying value of investment made in L7 Defense Limited has been considered as ₹ Nil as at March 31, 2024.
- 4** The Company is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 5** Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune
Date: May 06, 2025.



For and on behalf of the Board of Directors

Kailash Katkar
Chairman & Managing Director
DIN No: 00397191

QUICK HEAL TECHNOLOGIES LIMITED


Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408


STATEMENT OF STANDALONE AUDITED ASSETS AND LIABILITIES AS AT MARCH 31, 2025

? in crores

	As at March 31, 2025 (Audited)	As at March 31, 2024 (Audited)
Assets		
Non-current assets		
(a) Property, plant and equipment	83.15	83.61
(b) Capital work-in-progress	0.05	3.06
(c) Investment property	35.01	31.62
(d) Intangible assets	0.72	1.49
(c) Right-of-use assets	0.33	-
(f) Investments in subsidiaries	0.81	0.81
(g) Financial assets		
(i) Investments	7.28	7.45
(ii) Other financial assets	0.89	0.82
(h) Deferred tax assets (net)	7.94	3.40
(i) Income tax assets (net)	17.20	16.46
(j) Other non-current assets	1.35	0.91
	154.73	149.63
Current assets		
(it) Inventories	2.22	2.80
(b) Financial assets		
(i) Investments	172.01	182.51
(ii) Trade receivables	170.36	132.05
(iii) Cash and cash equivalents	17.10	36.46
(iv) Bank balances other than (iii) above	0.13	0.25
(v) Other financial assets	1.26	1.26
(c) Other current assets	7.86	7.65
	370.94	362.98
Total assets	525.67	512.61
Equity and liabilities		
Equity		
(a) Equity share capital	54.00	53.51
(b) Other equity	387.84	383.39
Total equity	441.84	436.90
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	0.09	-
(b) Employee benefit obligations	0.74	-
(c) Other non-current liabilities	4.02	2.33
	4.85	2.33
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	3.52	3.70
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	31.84	36.40
(ii) Other financial liabilities	1.71	3.82
(b) Employee benefit obligations	18.11	15.57
(c) Other current liabilities	23.79	13.88
(d) Income tax liabilities (net)	0.01	0.01
	78.98	73.38
Total liabilities	83.83	75.71
Total equity and liabilities	525.67	512.61



Quick Heal Technologies Limited Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408		
STANDALONE AUDITED CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2025		
	? in crores	
	March 31, 2025	March 31, 2024
	Audited	Audited
A. Cash flow from operating activities		
Profit before tax	1.53	26.04
Adjustment to reconcile profit before tax to net cash flows:		
Net (gain)/ loss foreign exchange differences	(0.10)	0.15
Employee share based payments expense	9.95	5.10
Interest on lease	0.22	0.13
Rent equalisation	(0.21)	(0.12)
Depreciation and amortization expense	12.96	12.60
Interest income	(0.78)	(1.43)
Provision for doubtful debts and advances	3.27	7.15
Property, plant and equipment written off	-	0.32
(Profit) on sale of property, plant and equipment	(0.13)	(0.27)
Income from Investment Property	(5.49)	(4.99)
Net gain on sale of investment	(2.16)	(2.02)
Unrealised gain on investments	(11.30)	(10.23)
Operating profit before working capital changes	7.76	32.43
Movements in working capital:		
Increase in trade receivables	(41.48)	(16.58)
Decrease in inventories	0.58	1.70
(Increase)/ decrease in other financial assets	(0.10)	0.50
(Increase) in other assets	(0.44)	(1.18)
Increase in net employee benefit obligations	3.03	14.18
Decrease in trade payables	(4.74)	(8.58)
Decrease in other financial liabilities	(0.15)	(10.23)
Increase in other current and non-current liabilities	11.38	6.15
Cash (used in)/ generated from operations	(24.16)	18.39
Income taxes paid (net of refund)	(0.85)	0.03
Net cash flow (used in)/ generated from operating activities (A)	(25.01)	18.42
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(14.42)	(7.56)
Proceeds from sale of property, plant and equipment	0.34	1.08
Purchase of investment in mutual funds	(265.10)	(279.68)
Proceeds from sale of investment in mutual funds	289.06	286.21
Rental income from investment property	5.49	4.99
Decrease in Deposits with remaining maturity of more than twelve months	0.14	0.02
Income interest received	0.46	1.09
Net cash flow generated from investing activities (B)	15.97	6.15
C. Cash flow from financing activities		
Dividend paid	(16.13)	(13.29)
Principal paid on lease liabilities	(0.10)	-
GST refund on buy back expenses	-	0.14
Refund of buy back tax	-	8.60
Proceeds from issuance of equity shares (including securities premium) on exercise of employee stock options	5.91	6.15
Net cash flow (used in)/ generated from financing activities (C)	(10.32)	1.60
Net (Decrease)/ increase in cash and cash equivalents (A+B+C)	(19.36)	26.17
Cash and cash equivalents at the beginning of the year	36.46	10.29
Cash and cash equivalents at the end of the period	17.10	36.46
Components of cash and cash equivalents		
Cash on hand	0.01	0.01
Balances with banks		
On current account	9.89	6.06
On EEFC account	1.63	2.32
Deposits with original maturity of less than three months	5.57	28.07
Total cash and cash equivalents	17.10	36.46



Quick Heal Technologies Limited Reports Q4 FY25 Results

Pune, 6th May 2025: Quick Heal Technologies Limited, a global cybersecurity solutions provider, today announced its audited financial results for the quarter and fiscal year ended March 31, 2025.

Key Financial Highlights:

Particulars (₹ Cr)	Q4 FY24	Q4 FY25	FY25
Revenue	80.0	65.1	279.5
EBITDA	10.0	(8.5)	(6.6)
EBITDA Margin	12.6%	-13%	-2.4%
PAT	14.0	(3.3)	5.0
PAT Margin	17.5%	-5%	1.8%

Vishal Salvi, Chief Executive Officer, Quick Heal Technologies Limited, stated, *“I am excited to launch our version of Generative AI, SIA, to enable simplified security for our product stack. The successful launches of Seqrite Intelligent Assistant (SIA) and Seqrite Malware Analysis Platform (SMAP) have established new revenue streams, while our Threat Intelligence solution secured its first major enterprise order. The Quick Heal Academy continues to serve as a strategic entry point for large corporates and universities, with five new customer order signed this quarter. Our revamped sales organization is now positioned to execute complex cybersecurity projects at scale. We have been tirelessly working towards strategic project wins from the government and it gives me immense pleasure to state that we have closed a large deal.”*

Ankit Maheshwari, Chief Financial Officer, Quick Heal Technologies Limited, added, *“Growth has been subdued on account of deferred government deals and headwinds in consumer business. While the DPDP Act deferral has temporarily impacted regulatory-driven demand, our Data Privacy Suite remains market-ready. We continue to invest heavily in R&D because that is the core DNA of the cybersecurity business. We have launched multiple products through the year in the Horizon-3 category as we had committed. Following prudent accounting principles, we expense all the R&D investments in the P&L. We are fueling our Sales motion through investments in people, channels and marketing events. As we continue to launch new products, our momentum on order book and deferred revenue remains strong. We are committed to lasting shareholder value creation through right investments in the business at the right time.”*

Introduction of Seqrite Intelligent Assistant (SIA):

SIA – Seqrite Intelligent Assistant, is an AI-powered virtual security analyst designed to empower enterprises with unmatched clarity, speed, and resilience in cybersecurity operations.

Built on the foundation of GoDeep.AI, our proprietary, self-aware malware-hunting engine, and developed by the exceptional minds at Seqrite Labs & Engg Teams, SIA enables security teams to streamline investigations, automate repetitive tasks, and receive precise, real-time threat insights through a natural language interface. It remembers ongoing conversations, connects incidents intelligently, and

provides instant, actionable recommendations—helping organizations move from reactive to proactive defense, with ease.

Key Highlights of Q4 FY25 /FY25 Include:

- **Introduction of SIA:** Seqrite Intelligent Assistant (SIA) made available to Seqrite XDR users, to be rolled out across Seqrite’s comprehensive suite of cybersecurity solutions.
- **Launch of SMAP & Threat Intelligence:** Successfully rolled out AntiFraud.AI, Seqrite Malware Analysis Platform (SMAP) and Seqrite Threat Intelligence Platform (STI) to provide real-time threat intelligence and situational awareness.
- **Regional Threat Reports:** Released localized cyber threat analyses for key IT hubs Karnataka and Telangana along with national release of Annual Cyber Threat Report.
- **Inaugurated BIRD Cybersecurity Lab:** State-of-the-art cybersecurity lab designed to provide hands-on training and skill development for officials in RFIs
- **Expansion of Quick Heal Academy:** Started onboarding large organizations through Cyber Academy awareness program, erstwhile limited to universities.
- **Industry Recognition:** Seqrite Endpoint Protection (EPP) honored with the AV-TEST Best Performance 2024 Award for Corporate Users.
- **Women Entrepreneur in Cyber** won by Sneha Katkar at Future Crime research foundation.
- **Corporate Social Responsibility:** Quick Heal Foundation touched 64 lakh+ lives through its initiatives; the Cyber Shiksha for Cyber Suraksha Awards honored participating colleges and students for cybersecurity awareness efforts.

As Quick Heal Technologies Limited enters FY26, the company remains steadfast in its goal to simplify cybersecurity for enterprises and individuals alike. With a strategic focus on AI-driven innovation, academia-industry collaborations, and scalable threat intelligence frameworks, the company is poised to address the evolving cybersecurity challenges of the digital age. Sustained investments in R&D, coupled with its expanding global partnerships and award-winning solutions, reinforce the company’s commitment to building secure digital ecosystems. By continuing to align its offerings with emerging regulatory requirements and market demands, Quick Heal Technologies Limited reaffirms its position as a trusted guardian of cyberspace for businesses, governments, and citizens worldwide.

About Quick Heal Technologies Limited

Quick Heal Technologies Limited is a leading global cybersecurity solutions provider. Incorporated in 1995 with a registered office in Pune, it offers end-to-end cybersecurity solutions across B2C, B2B, and B2G segments. With its widely recognized brands ‘Quick Heal’ and ‘Seqrite’, the company provides AI-powered, patented technologies that protect endpoints, networks, data, mobility, and cloud environments. Committed to R&D and innovation, Quick Heal Technologies continues to simplify security by delivering best-in-class protection against advanced cyber-threats to millions of customers, enterprises, and government organizations worldwide.



SEGRITE

Quick Heal

Earnings Presentation: FY25

6th May 2025



Global Cybersecurity Trends

- ⦿ Consolidation of security stack
- ⦿ Investment & adoption of Generative AI in Cybersecurity
- ⦿ Privacy driven Application & Data Decoupling
- ⦿ Growing Adoption of Cloud Native Application
- ⦿ Cybersecurity reskilling
- ⦿ Organizations continue to accelerate their multiyear Security Service Edge (SSE) and Zero Trust (ZT) journey.
- ⦿ Organizations continue to strengthen their security portfolio with new tools





India Cyber Threat Report: Key Highlights

Bigger spectrum of
detections and endpoints

Over
369.01 million
detections recorded
across **8.44**
Million
endpoints

Averaging **702**
detections
per minute

Behavioral-based
detection

53.73 million
behavior-based detections,
accounted for **14.56%**
of total detections

Significant increase
from **12.5%** in 2023

~12 attacks per
month per
personal end
user device

Primary attack vectors

68%
of attacks originated from
Trojans and Infectors

Cloud detections
contributed

62%
while 38% detections
were on-premise





India Cyber Threat Report: Key Highlights Cont...

Geographical Hotspots

Telangana 15.03% of detections		Tamil Nadu 12% of detections
Surat 14.6% of detections	Bengaluru 12% of detections	Jaipur 11.72% of detections

Top most targeted industries



Malware and Ransomware incidents





Our Purpose

Innovate to “simplify” securing digital experience



Innovate

Focus on grassroot research and adoption of new tech



Simplify

Ease of manageability & operations for the end customers



Secure

Getting the Job Done: Staying one step ahead of the threat actors to protect our customers





Our Journey so far

1993-96

Protected early Generations of PCs

1996-00

Secured PCs, Network & Emails

2001-05

Ensured a safe digital experience for
Individuals, Businesses and Government
Organizations

2006-10

Threat protection for Smart Phones and
Tablets



2011-16

Global Footprint, Foray into enterprise
Segment with SEQRITE, & listed on BSE & NSE

2017-19

Protecting Data, Transactions & Cloud
transitions

2020-23

Protecting Data, Transactions & Cloud
transitions

2023-25

- ⦿ Professional CEO onboard
- ⦿ CSMA Product Stack
- ⦿ Horizon-2 & 3 Product launches
- ⦿ Experience Centre
- ⦿ Leadership Strengthening
- ⦿ India Cyber Threat Report
- ⦿ Brand Refresh
- ⦿ SIA Launch



This is us



Pioneer of
cybersecurity
in India



1st Listed
Cybersecurity
company in India



Market
Leader
in India



Collaborators with
US bodies
NIST & AISIC



Protecting
9 Million
Active Devices



Patents



Presence in **70+**
countries



1000+
Cybersecurity
Professionals



Proud
Partners



Proud Owners of **Seqrite Labs**: Largest in
the country



Founded by the visionaries



Dr. Kailash Katkar
Managing Director

A Visionary Founder and Leader, a Born Entrepreneur, and an Exemplary Trailblazer, he has transformed Quick Heal into a beacon of success and innovation in the Cybersecurity industry. His business acumen has consistently driven Remarkable financial performance, customer satisfaction, market leadership making Quick Heal & SEQRITE the preferred choice for customers globally.



Dr. Sanjay Katkar
Joint Managing Director

Dr. Sanjay Katkar: Co-Founder of Quick Heal Technologies Limited, Joint Force, and Technology Powerhouse behind the company's journey. An unmatched Cybertech Mastermind, who is relentlessly shaping the company's global technology strategy and driving core research and development while pursuing product innovation to fortify cyber security.



Vishal Salvi

Chief Executing Officer

A Prominent Global Leader, and Distinguished Cybersecurity Expert with a remarkable three-decade journey transforming the cybersecurity and information technology for global brands

His recent role was Global Chief Information Security Officer and Business Head of the Cybersecurity Service Line at Infosys Ltd. He was previously associated with reputed organizations: HDFC Bank, Standard Chartered Bank & PWC.

Led by the Industry Experts



Ajit Zanjad
VP & Head of Delivery



Ankit Maheshwari
Chief Financial Officer



Anupama Katkar
Chief of Operational
Excellence



Ashish Pradhan
Chief Technical Officer



Ashish Kadam
Director, Government Business



Deepak Mishra
Head, Retail Sales



Dr. Lalit Mohan
Chief Product Officer



Samuel Sathayjith
Senior VP, Enterprise Sales



Sangamesh S
Head of Seqrite Labs



Sudhanshu Tripathi
Chief Marketing Officer



Swapna Sangari
VP, People & Culture



Our Strategy & Way Forward



Expanding Across 3 Levers

Geographic Reach

*Setting up a strong foot in
Indian Market
Strategic Expansion in select
focused geographies*

Large Customers


*Moving up the customer segments as
the solutions mature
Niche Solutions specifically targeted
to Large Enterprises (SDP, SMAP, STI)*

Product Stack:

*Holistic cybersecurity stack for
better protection and increased
wallet share
Increasing our coverage by
launching new products*




Seqrite Solution Stack




An approach to simplify cybersecurity by integrating security tools across a distributed enterprise

Cybersecurity Market Landscape: Our Targeted Play






Expanding Serviceable Operatable Market



Levers of SOM Growth



Source: Market Research & Company Estimates



Our Right to Win

- 🎯 Largest Cybersecurity Lab in India with unique telemetry
- ® Holistic platformized cybersecurity solution
- ® Simple Integrated Architecture
- ® Solving unique value propositions & use cases (E.g.: On prem & cloud)
- ® Best in class support offerings
- ® Adoption of the new age tech in our stack
- ® Make in India
- ® Strong Partner Network across the country
- ® Proximity to the customers in India





Awards & Recognition

Quick Heal is certified as one of the safest for browsing & banking by AVLab, Poland



Quick Heal is certified the "Product of the year" by AVLab, Poland



Seqrite Endpoint Protection for Best Performance by AV-Test




Seqrite Endpoint Protection Achieves AV-TEST Approved – Top Product Corporate Endpoint Protection





Strategic Collaborations





Thought Leadership & Brand Strengthening

Thought Leadership

- Seqrite launches "**India Cyber Threat Report 2025**" with DSCI - *Threat Report launched by Shri S. Krishnan, Secretary, MeitY.*
- Experience Centre

Brand Building

- Speaker sessions, sponsorships and presence in major cybersecurity events
- Brand Refresh
- ATL Campaigns
- ESG focused business

Awards & Recognition

- AV Test certifications
- Consortium Member of the US Artificial Intelligence Safety Institute
- Ranked **4.6/5** in Gartner peer insights.





Q4 FY25 - Business Highlights




Business Highlights

- **Launched** SIA, Seqrite's Gen AI assistant to simplify cybersecurity for end customer.
- Strong **renewal** momentum for large accounts on New Products
- **Order Book:** INR 24+ Cr as on date
- **New Product Billing:** FY25 > 3x FY24
- **Deferred Revenue:** INR 12+ Cr
- **First Order** for Seqrite Threat Intelligence Received
- Strategic account wins through Academy vertical






SIA: Seqrite Intelligent Assistant






Deconstructing Current Business







Enterprise Business Cloud & Non-Cloud



FY 2023



FY 2024



FY 2025

■ Non-Cloud ■ Cloud

CAGR of cloud business is 47% in 2 years





FY25: Performance Highlights

₹ 279.5 Cr

Net Revenue
-4.2% YoY

₹ (6.6) Cr

EBITDA
-137.5% YoY

₹ 5.0 Cr

PAT
-79.2% YoY

₹ 0.91

Diluted EPS
-79.7% YoY

₹ 185.7 Cr

Consumer Revenue
-9.2% YoY


₹ 121.2 Cr

Enterprise Revenue
+1.5%YoY

*Based on gross revenues excluding deferred revenue, before adjusting for sales incentives



Market Leaders: Indian Consumer Antivirus Business



- 30 years into existence
- Market leadership with over 30% in the Indian market
- Robust Sales & Distribution network in India

Our Approach:

- Launched **AntiFraud.Ai** to tackle the financial frauds
- Focus towards maintaining our market share in AV segment
- Drive consumer awareness in the geography in cybersecurity specific domain



Consumer Marketing Campaigns



Indian Idol

SAT-SUN 8:30 TM

SONY ENTERTAINMENT TELEVISION

Quick Heal AntiFroud.AI

Spot the Stars, Dodge the scams.

Get it Free:

[Click Here](#)



Quick Heal

FATEH

JAB SONU KE SATH HO QUICK HEAL AntiFroud.AI TOH HOGI FATEH

INDIA'S FIRST FRAUD PREVENTION SOLUTION

Available on @ a. A | * * *



'VOICES OF TRUST'

DIGITAL SECURITY

CA. ANISH KELKAR

#GoDigitalFearlessly




Quick Heal

#MahaKumbh2025



Seqrite: Enterprise Arm of QH





Enterprise Marketing Campaigns



Seqrite a Gold Sponsor of the DSCI Data Protection Summit 2025 - Mumbai



Seqrite Featured on the IT Voice Magazine cover page with 50K Reach



Team Seqrite at India Options Conclave in Gujarat



Seqrite Unveiling The Karnataka Cyber Threat Report 2025



CSR Update FY25



Earn & Learn - Direct

4 States, 780 Volunteers

13,20,883
Lives Touched



Earn & Learn - InDirect

3 States, 120 Volunteers

1,34,006
People Reached



Street Play

3 States

54,009
People Reached

Total
Outreach: **64 Lacs+**

Total States
Covered: **10**

Maharashtra, Karnataka, Gujarat, West Bengal, Chhattisgarh, Uttar Pradesh, Assam, Punjab, Jammu & Kashmir, Madhya Pradesh



Financial Highlights



Consolidated P&L

PARTICULARS	Q4 FY24	Q3 FY25	Q4 FY25	FY24	FY25
Revenue	80.0	70.6	65.1	291.8	279.5
Direct Cost	1.9	1.9	1.8	7.9	8.0
Gross Profit	78.1	68.7	63.3	283.9	271.5
Gross Margin	97.6%	97.3%	97.2%	97.3%	97.1%
Operating Cost					
Research & Development	33.7	33.8	33.6	133.1	136.0
Sales and Marketing	20.5	23.7	23.8	80.2	86.6
General Administration	13.8	15.0	14.4	53.1	55.5
Total Expenditure	68.1	72.5	71.8	266.3	278.1
EBITDA	10.0	(3.8)	(8.5)	17.6	(6.6)
EBITDA %	12.6%	-5.3%	-13.0%	6.0%	-2.4%
Depreciation	3.2	3.4	3.6	12.6	13.0
EBIT	6.9	(7.2)	(12.1)	4.9	(19.6)
Other Income	6.8	4.9	5.6	21.4	20.8
Finance Cost	(0.1)	(0.1)	(0.1)	(0.1)	(0.2)
Profit Before Tax (PBT)	13.6	(2.3)	(6.6)	26.2	1.0
Tax	(0.5)	(2.4)	(3.3)	2.0	(4.0)
Profit After Tax (PAT)	14.0	0.1	(3.3)	24.2	5.0
PAT Margin	17.5%	0.2%	-5.0%	8.3%	1.8%

All values are in INR Cr, unless otherwise stated





Balance Sheet

EQUITY AND LIABILITIES	Mar 31, 2024	Mar 31, 2025
Equity		
Equity Share Capital	53.5	54.0
Share application money pending allotment	-	-
Reserves and Surplus	383.5	387.5
Total Shareholder Funds	437.0	441.5
Non-Current Liabilities		
Net employee defined benefit liabilities	-	0.7
Other Non Current Liabilities	2.3	4.1
Deferred tax liabilities (net)	-	0.0
Total Non-Current Liabilities	2.3	4.9
Current Liabilities:		
Trade and Other Payables	39.9	34.9
Other Financial Liabilities	3.8	1.8
Other Current Liabilities	14.0	23.9
Net employee defined benefit liabilities	15.6	18.1
Current tax liabilities (Net)	-	0.0
Total Current Liabilities	73.3	78.7
Total Equity & Liabilities	512.6	525.0


ASSETS	Mar 31, 2024	Mar 31, 2025
Non-Current Assets:		
Property, plant and equipment	83.6	83.2
Capital work-in-progress	3.1	0.1
Intangible assets	1.5	0.7
Investment Property	31.6	35.0
Right-of-use assets	-	0.3
Non-current financial assets		
Investments in MF, Tax-Free Bonds, Subs & others	7.5	7.3
Other Financial Asset	0.8	0.9
Deferred tax assets (net)	3.4	7.9
Other Non Current assets	17.4	18.6
Total Non-Current Assets	148.8	153.9
Current assets:		
Inventories	2.8	2.2
Investment in Mutual Fund	182.5	172.0
Trade and other receivables	131.7	166.7
Cash and Cash Equivalents	37.5	20.8
Bank Balance other than cash & cash equivalents	0.3	0.1
Other Financial Assets	1.3	1.3
Other Current assets	7.8	7.9
Total Current Assets	363.8	371.1
Total Assets	512.6	525.0

All values are in INR Cr, unless otherwise stated




Capital Market Data

Shareholding Pattern (as on 31st March 2025)



Stock Market Performance (as on 31st March 2025)



Price Data (as of 31st March 2025)

Face Value	10.00
Market Price	286.75
52 Week H/L	825.90/272.50
Market Cap (INR Mn)	15,486.39
Equity Shares Outstanding (Mn)	54.00
1 Year Avg. Trading Volume ('000)	291.48
1 Year Avg. Net Turnover (Mn)	170.31



Disclaimer

For further details, please feel free to contact our Investor Relations Representatives:



VALOREM ADVISORS

Mr. Anuj Sonpal
Valorem Advisors

Email: quickheal@valoremadvisors.com

Tel: +91-22-4903 9500

Investor Relations Officer

Mr. Deepak Kumar

Deepak.Kumar01@quickheal.com

Company Secretary

Mr. Sarang H Deshpande

cs@quickheal.com

+91-20-66813232

CIN No: L72200MH1995PLC091408

www.quickheal.co.in

Quick Heal Technologies Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward-looking statements" based on the currently held beliefs and assumptions of the management of Quick Heal Technologies Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results to differ materially from the results, financial condition, performance, or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment, and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties, and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations, or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration therefrom.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness, and reasonableness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.



Thank You

Simplifying Cybersecurity

Independent Auditor's Report on Consolidated Audited Annual Financial Results of the Quick Heal Technologies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of Quick Heal Technologies Limited

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Audited Annual financial results of **Quick Heal Technologies Limited** (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditor on separate audited financial statements of the subsidiaries, the aforesaid Statement:

(i) includes the annual financial results of Holding Company and the following entities:

Sr. No.	Name of the Entity	Relationship with the Holding Company
1	Quick Heal Technologies America Inc.	Wholly Owned Subsidiary
2	Seqrite Technologies DMCC	Wholly Owned Subsidiary

(ii) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit, and other comprehensive income and other financial information of the Group, for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.



Management's and Board of Directors' Responsibilities for the Consolidated Financial Results

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in accordance with the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditors' Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.



MSKA & Associates

Chartered Accountants

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters:

1. The Statement includes the audited financial results of two subsidiaries, whose Financial Statements reflect Group's share of total assets of Rs. 7.65 crores as at March 31, 2025, Group's share of total revenue of Rs. 5.64 crores, Group's share of total net profit after tax of Rs. 0.15 crores, and Group's share of total comprehensive income of Rs. 0.15 crores for the year April 01, 2024 to March 31, 2025 and Group's net cash inflow of Rs. 2.71 crores for the year ended as on date, as considered in the Statement, which have been audited by the other auditor whose reports on financial statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Subsidiaries, is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.

Our opinion is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.



MSKA & Associates

Chartered Accountants

2. The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration NO.105047W

S. Khivasara

Shraddha D Khivasara

Partner

Membership No.: 134285

UDIN: 25134285BM NTOC7003



Place: Pune

Date: May 06, 2025

Independent Auditor's Report on Standalone Audited Annual Financial Results of the Quick Heal Technologies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of Quick Heal Technologies Limited

Report on the Audit of Standalone Financial Results

Opinion

We have audited the accompanying statement of standalone annual financial results of **Quick Heal Technologies Limited** (hereinafter referred to as 'the Company') for the year ended March 31, 2025 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) is presented in accordance with the requirements of the Listing Regulations in this regard; and
- (ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit, and other comprehensive income and other financial information of the Company for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended, issued thereunder and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of



MSKA a Associates

Chartered Accountants

appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the financial reporting process of the Company.

Auditors' Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



MSKA & Associates

Chartered Accountants

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter:

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W

SD Khivasara



Shraddha D Khivasara

Partner

Membership No. 134285

UDIN: 25134285BMNTDE 8667

Place: Pune

Date: May 06, 2025